NU.V - NeutriSci International Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0250
-0.0050 (-16.67%)
At close: 1:36PM EDT
Stock chart is not supported by your current browser
Previous Close0.0300
Open0.0250
Bid0.0250 x 0
Ask0.0300 x 0
Day's Range0.0250 - 0.0250
52 Week Range0.0200 - 0.0950
Volume41,000
Avg. Volume231,891
Market Cap3.604M
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Distribution of NeutriSci's THC/CBD Products to Commence in California

    VANCOUVER, BC / ACCESSWIRE / March 13, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (NRXCF)(NU.V)(1N9.F) is pleased to announce that Cryopharm Corp. ("Cryopharm"), its US manufacturing and distribution partner, is completing the packaging of NeutriSci and Cryopharm's CBD/THC products in preparation for initial distribution to more than 90 dispensaries across the state of California, with the distribution network expected to grow to over 350 dispensaries in Q2/2020. NeutriSci's core ingredients form the basis of Marbl Melts™, which contain a clinically tested dosage providing on-set in as little as 12 minutes; compared to traditional cannabinoid infusion methods that often have incorrect dosages while potentially taking up to 120 minutes to become active. NeutriSci's Zenstix™ and Dablets™: quick melting tabs that activate faster when compared to other cannabis edibles with a powerful 10mg dose.

  • ACCESSWIRE

    NeutriSci Closes $518,000 Financing

    VANCOUVER, BC / ACCESSWIRE / March 5, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (NU.V)(NRXCF)(1N9.F) the innovator and pioneer behind neuenergy® is pleased to announce that it has closed on the final tranche of its non-brokered private placement (the "Placement") announced on January 16, 2020 and February 18, 2020, in which it raised proceeds of $518,000. Each Unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire an additional common share of the Company at a price of $0.05 until September 5, 2021. In connection with this tranche of the Placement, the Company paid a finder's fee of $700.

  • ACCESSWIRE

    NeutriSci Increases Financing To $1.15 Million

    VANCOUVER, BC / ACCESSWIRE / February 18, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU, OTCQB:NRXCF, FRANKFURT:1N9) the innovator and pioneer behind neuenergy® is pleased to announce that it has elected to increase the size of the non-brokered private placement (the "Placement") originally announced on January 16, 2020. On January 24, 2020, the Company closed on the first tranche of the Placement, in which it raised proceeds of $655,000. Due to increased investor demand, the Company now intends to raise up to an additional $495,000 (the "Second Tranche") through the issuance of up to 9,900,000 units (the "Units") of the Company at a price of $0.05 per Unit.

  • ACCESSWIRE

    NeutriSci Closes $655,000 Financing

    VANCOUVER, BC / ACCESSWIRE / January 24, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU, OTCQB:NRXCF, FRANKFURT:1N9) the innovator and pioneer behind neuenergy® is pleased to announce that it has closed on the first tranche of its non-brokered private placement (the "Placement") announced on January 16, 2020, in which it raised proceeds of $655,000. Each Unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire an additional common share of the Company at a price of $0.05 until July 24, 2021. All securities issued in connection with this tranche of the Placement are subject to a hold period expiring May 25, 2020.

  • ACCESSWIRE

    NeutriSci Withdraws Share Consolidation and Plans $0.05 Private Placement Financing

    VANCOUVER, BC / ACCESSWIRE / January 16, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (NU.V)(NRXCF), (1N9.F) the innovator and pioneer behind neuenergy® is pleased to announce that it will not be proceeding with the proposed financing or consolidation as announced on December 18, 2019. The Company will instead complete a non-brokered private placement offering (the "Offering"), of units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of up to $725,000. Subscriptions to the financing have been received and closing of an initial tranche is expected shortly.

  • The NeutriSci International (CVE:NU) Share Price Is Down 76% So Some Shareholders Are Rather Upset
    Simply Wall St.

    The NeutriSci International (CVE:NU) Share Price Is Down 76% So Some Shareholders Are Rather Upset

    It's not a secret that every investor will make bad investments, from time to time. But it would be foolish to simply...

  • GlobeNewswire

    NeutriSci Expands Partnership With Cryopharm and Nutritional High

    Under the expanded terms, in addition to manufacturing its own product, Marbl Melts™, Cryopharm will also manufacture NeutriSci’s ZenStix™ and Dablets™ utilizing its manufacturing and infusion license at its manufacturing facility in Sacramento, California. Ryan Erving, COO of Cryopharm commented, “We are excited to partner with NeutriSci and Nutritional High for the production and sale of our Marbl Melts, and the Dablet and Zenstix line of products.

  • GlobeNewswire

    NeutriSci Announces Initial Order From Cryopharm

    NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has received an initial order from Cryopharm Corporation (“Cryopharm”). NeutriSci licensed its Cryolization technology to Cryopharm for the manufacturing and distribution of buccal and sublingual rapid release consumable products utilizing both CBD and THC molecules.  Cryopharm has placed its order for NeutriSci’s core ingredients, which form the basis of the company’s Marbl Melts.  In addition to purchasing the core ingredients from NeutriSci, under the licensing terms, Cryopharm will pay NeutriSci a license fee, and a royalty on gross sales.

  • GlobeNewswire

    NeutriSci and Thai Freeze Dry Join Forces to Develop New Product Line of Cannabis Edibles

    The pilot formulation development and testing program to be conducted under this LOI shall focus on creation of test formulations of NeutriSci’s patented technology tablets to be modified through incorporation of TFD’s proprietary technology together with cannabinoids and other ingredients under TFD’s umbrella of products. Testing will be conducted at TFD’s facilities in Chiang Mai, Thailand.

  • GlobeNewswire

    NeutriSci International Announces Exclusive Distribution Deal

    NeutriSci International Inc. ("NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy® is pleased to announce effective May 1st, 2019 ANB Canada Inc. (“ANB”) will assume all responsibilities for retail sales and distribution of neuenergy® products in Canada. ANB not only markets, sells, warehouses and distributes consumer OTC brands, but also helps manufacturers in several areas, including generating brand awareness. ANB currently represents the brands of many manufacturers across many different product lines.